ERBB2 and breast cancer: Furthermore, recent research by Du et al. (2023) suggests that PDPN+-CAFs contribute to HER-2-positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.